Feasibility of using an epigenetic marker of risk for lung cancer, methylation of p16, to promote smoking cessation among US veterans

Scott Shofer, Matthew Beyea, Sufeng Li, Lori A Bastian, Momen M Wahidi, Michael Kelley, Isaac M Lipkus, Scott Shofer, Matthew Beyea, Sufeng Li, Lori A Bastian, Momen M Wahidi, Michael Kelley, Isaac M Lipkus

Abstract

Introduction: Providing smokers feedback using epigenetic markers of lung cancer risk has yet to be tested as a strategy to motivate smoking cessation. Epigenetic modification of Rb-p16 (p16) due to tobacco exposure is associated with increased risk of developing lung cancer. This study examined the acceptance of testing for methylated p16 and the understanding of test results in smokers at risk for development of lung cancer.

Methods: Thirty-five current smokers with airways obstruction viewed an educational presentation regarding p16 function followed by testing for the presence of methylated p16 in sputum. Participants were offered smoking cessation assistance and asked to complete surveys at the time of enrolment regarding their understanding of the educational material, perception of risk associated with smoking and desire to quit. Participants were notified of their test result and follow-up surveys were administered 2 and 10 weeks after notification of their test result.

Results: Twenty per cent of participants had methylated p16. Participants showed high degree of understanding of educational materials regarding the function and risk associated with p16 methylation. Sixty-seven per cent and 57% of participants with low-risk and high-risk test results, respectively, reported that the information was more likely to motivate them to quit smoking. Smoking cessation rates were similar between methylated and non-methylated participants.

Conclusions: Testing for an epigenetic marker of lung cancer risk is accepted and understood by active smokers. A low-risk test result does not decrease motivation to stop smoking.

Trial registration number: NCT01038492.

Keywords: Lung Cancer; Tobacco and the lung.

References

    1. Siegel R, Ma J, Zou Z, et al. . Cancer statistics, 2014. CA Cancer J Clin 2014;64:9–29
    1. Wingo PA, Ries LA, Giovino GA, et al. . Annual report to the nation on the status of cancer, 1973–1996, with a special section on lung cancer and tobacco smoking [see comment]. J Natl Cancer Inst 1999;91:675–90
    1. Sarna L, Bialous SA, Nandy K, et al. . Changes in smoking prevalences among health care professionals from 2003 to 2010-2011. JAMA 2014;311:197–9
    1. Fiore M, Jaen C, Baker T, et al. . Treating tobacco use and dependence: 2008 update. Clinical practice guideline. U.S. Department of Health and Human Services. Public Health Service: Rockville, MD, 2008
    1. Bize R, Burnand B, Mueller Y, et al. . Biomedical risk assessment as an aid for smoking cessation. Cochrane Database Syst Rev 2012;12:CD004705.
    1. Bize R, Burnand B, Mueller Y, et al. . Biomedical risk assessment as an aid for smoking cessation. Cochrane Database Syst Rev 2009;(2):CD004705
    1. Lerman C, Gold K, Audrain J, et al. . Incorporating biomarkers of exposure and genetic susceptibility into smoking cessation treatment: effects on smoking-related cognitions, emotions, and behavior change. Health Psychol 1997;16:87–99
    1. Audrain J, Boyd NR, Roth J, et al. . Genetic susceptibility testing in smoking-cessation treatment: one-year outcomes of a randomized trial. Addict Behav 1997;22:741–51
    1. McBride CM, Halabi S, Bepler G, et al. . Maximizing the motivational impact of feedback of lung cancer susceptibility on smokers’ desire to quit. J Health Commun 2000;5:229–41
    1. Hishida A, Terazawa T, Mamiya T, et al. . Efficacy of genotype notification to Japanese smokers on smoking cessation—an intervention study at workplace. Can Epidemiol 2010;34:96–100
    1. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107–16
    1. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nature Rev Genet 2006;7:21–33
    1. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683–92
    1. Belinsky S, Nikula K, Palmisano W, et al. . Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci 1998;95:11891–6
    1. Belinsky SA, Nikula KJ, Palmisano WA, et al. . Aberrant methylation of p16 (INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998;95:11891–6
    1. Issa JP, Baylin SB, Belinsky SA. Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure. Cancer Res 1996;56:3655–8
    1. Kim DH, Nelson HH, Wiencke JK, et al. . p16 (INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 2001;61:3419–24
    1. Liu Y, Lan Q, Siegfried JM, et al. . Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. Neoplasia (New York) 2006;8:46–51
    1. Toyooka S, Maruyama R, Toyooka KO, et al. . Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 2003;103:153–60
    1. Toyooka S, Tokumo M, Shigematsu H, et al. . Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res 2006;66:1371–5
    1. Belinsky SA, Liechty KC, Gentry FD, et al. . Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006;66:3338–44
    1. Belinsky S, Palmisano W, Gilliland F, et al. . Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002;62:2370–7
    1. Sanderson S, O'Neill S, White D, et al. . Responses to online GSTM1 genetic test results among smokers related to patients with lung cancer: a pilot study. Cancer Epidemiol Biomarkers Prev 2009;18:1953–61
    1. Parkes G, Greenhalgh T, Griffin M, et al. . Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ 2008;336:598–604

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere